Skip to Content
Søk Menu

5-Years Data: High-Dose Thoracic Radiotherapy Increases OS Significantly for Patients with Limited Stage of Small-Cell Lung Cancer

Compared with low-dose thoracic radiotherapy, a high dose twice daily can increase overall survival (OS) from 22.6 months to 43.6 months. In this MEDtalk, Bjørn Henning Grønberg, NTNU, Trondheim, Norway, presents interesting data from the study.
Bjørn H Grønberg

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Vivi Quoc Nguyen

Carboplatin is a Viable Option in Treating Patients with Completely Resected Non-Small Cell Lung Cancer

/ Vivi Quoc Nguyen
Lungekreft Play the Video 1:44
Odd Terje Brustugun

Onkologisk Forum: Highlights in Lung Cancer Treatment

/ Odd Terje Brustugun
LungekreftOnkologiskForum23 Play the Video 5:22
Nathan Harrison

Interventions Designed to Reduce Lung Cancer Stigma

/ Nathan Harrison
LungekreftWCLC23 Play the Video 7:15
Jonathan Spicer

Perioperative Pembrolizumab Shows Significant OS in ResectableNon-Small-Cell Lung Cancer

/ Jonathan Spicer
ESMO23Lungekreft Play the Video 4:01

Highlights from ASCO 2023 – New Insights into Luminal Breast Cancer

/ Bent Ejlertsen
ASCO23Brystkreft
Masahiro Tsuboi

Efficacy of Osimertinib in resected EGFR-Mutated stage IB-IIIA NSCLC

/ Masahiro Tsuboi
Lungekreft Play the Video 7:07

WCLC 2023 – NSCLC: New Data on Perioperative Immunotherapy Treatment 

/ BestPractice Nordic
ImmunterapiLungekreftNSCLCWCLC23

Adjuvant treatment with 3rd generation EGFR-TKI can increase progression-free survival 

/ BestPractice Nordic
LungekreftNSCLCWCLC23

CheckMate 227: 6-year data on the treatment of locally advanced NSCLC with Opdivo and Yervoy  

/ BestPractice Nordic
LungekreftNSCLCWCLC23
Back to top